Published in Neurology on November 26, 2002
Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet (2011) 1.60
Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Neurology (2015) 1.42
PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. PLoS One (2011) 1.12
Genetic neuropathology of Parkinson's disease. Int J Clin Exp Pathol (2008) 1.11
Autosomal dominant cerebellar ataxia type I: a review of the phenotypic and genotypic characteristics. Orphanet J Rare Dis (2011) 0.98
Model organisms reveal insight into human neurodegenerative disease: ataxin-2 intermediate-length polyglutamine expansions are a risk factor for ALS. J Mol Neurosci (2011) 0.95
Psychotic-affective symptoms and multiple system atrophy expand phenotypes of spinocerebellar ataxia type 2. BMJ Case Rep (2012) 0.85
Parkinsonism in spinocerebellar ataxia. Biomed Res Int (2015) 0.77
Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [123I]beta-CIT SPECT analysis. Eur J Nucl Med Mol Imaging (2006) 0.75
Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol (2016) 0.75
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Multiple receptors for dopamine. Nature (1979) 5.51
Double-blind study of botulinum toxin in spasmodic torticollis. Lancet (1986) 4.54
Phenotypic correlations in FTDP-17. Neurobiol Aging (2001) 3.96
Levodopa failure in chronic manganism. Neurology (1994) 3.80
Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat Genet (1993) 3.58
Audit of gonorrhoea test of cure at the genitourinary medicine department in Newcastle upon Tyne, UK. Int J STD AIDS (2003) 3.21
Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science (2001) 3.18
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology (2012) 3.12
Ligand-regulated transport of the Menkes copper P-type ATPase efflux pump from the Golgi apparatus to the plasma membrane: a novel mechanism of regulated trafficking. EMBO J (1996) 3.04
The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2002) 2.81
L-dopa in postencephalitic parkinsonism. Lancet (1969) 2.72
A scoring error in the Mini-Mental State test. Can J Psychiatry (1993) 2.69
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology (1983) 2.47
Bromocriptine in Parkinsonism. Br Med J (1974) 2.44
Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet (1992) 2.39
Energy expended playing Xbox Kinect™ and Wii™ games: a preliminary study comparing single and multiplayer modes. Physiotherapy (2012) 2.34
Bilateral human fetal striatal transplantation in Huntington's disease. Neurology (2002) 2.34
Aetiology of Parkinson's disease. Lancet (1984) 2.32
Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol (2001) 2.31
alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci (1999) 2.25
A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med (1998) 2.20
Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol (1990) 2.18
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology (2008) 2.16
Management of Parkinson's disease a review of current and new therapies. Can J Neurol Sci (1999) 2.16
Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. Am J Med Genet A (2003) 2.15
alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet (2001) 2.07
Vocal cord paralysis in the Shy-Drager syndrome. J Neurol Neurosurg Psychiatry (1979) 2.04
Screening for alcohol use disorders in a genitourinary medicine setting. Int J STD AIDS (2011) 2.02
Manganese neurotoxicity: a review of clinical features, imaging and pathology. Neurotoxicology (1999) 1.97
TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology (2010) 1.93
Reaction time in Parkinson's disease. Brain (1981) 1.92
Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. Neurology (2002) 1.90
Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology (2004) 1.87
X-linked scapuloperoneal syndrome. J Neurol Neurosurg Psychiatry (1972) 1.87
Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology (2004) 1.86
A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience (2007) 1.86
L-dopa in idiopathic parkinsonism. Lancet (1969) 1.86
A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet (1998) 1.84
Hypotension caused by L-dopa. Br Med J (1970) 1.81
Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol (2000) 1.79
Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord (2002) 1.79
Positron emission tomography in manganese intoxication. Ann Neurol (1989) 1.78
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
alpha-Synuclein and Parkinson disease susceptibility. Neurology (2007) 1.72
Mutations in the murine homologue of the Menkes gene in dappled and blotchy mice. Nat Genet (1994) 1.71
The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol (1992) 1.67
Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotrophic interaction between ageing and environment? Lancet (1986) 1.65
In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol (2000) 1.65
Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol (1999) 1.65
Characterization of ehrlichial organisms isolated from a wild mouse. J Clin Microbiol (1993) 1.64
A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation. Ann Neurol (1995) 1.64
Cardiovascular reflexes in Parkinsonism. Clin Sci (1971) 1.62
Study of a Swiss dopa-responsive dystonia family with a deletion in GCH1: redefining DYT14 as DYT5. Neurology (2007) 1.62
Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill (2011) 1.61
Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J (1971) 1.60
PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology (2008) 1.60
Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. Heart (2001) 1.60
Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology (1996) 1.60
CFS hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry (1980) 1.59
Selegiline in Parkinson's disease. BMJ (1995) 1.58
Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma. J Gastroenterol Hepatol (2001) 1.55
Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid. J Lab Clin Med (1997) 1.52
Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J Neurol Neurosurg Psychiatry (2000) 1.49
Head injury, α-synuclein genetic variability and Parkinson's disease. Eur J Neurol (2014) 1.48
Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN. Neurology (2009) 1.48
Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis (2001) 1.48
Motor nerve conduction velocity in peroneal muscular atrophy: evidence for genetic heterogeneity. J Neurol Neurosurg Psychiatry (1974) 1.47
Development of a DNA probe from the deoxyribonucleotide sequence of a 3-N-aminoglycoside acetyltransferase [AAC(3)-I] resistance gene. Antimicrob Agents Chemother (1989) 1.47
Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol (1991) 1.46
Clinical and pathologic features of families with LRRK2-associated Parkinson's disease. J Neural Transm Suppl (2006) 1.46
Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology (2006) 1.45
Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol (1997) 1.45
Environmental exposures in elderly Canadians with Parkinson's disease. Can J Neurol Sci (1995) 1.43
Mutations in GTP-cyclohydrolase I gene and vitiligo. Lancet (1997) 1.43
Evaluation of cerebellar size in attention-deficit hyperactivity disorder. J Child Neurol (1998) 1.42
The reproducibility of striatal uptake data obtained with positron emission tomography and fluorine-18-L-6-fluorodopa tracer in non-human primates. J Nucl Med (1991) 1.42
Action of dopamine on the human iris. Br Med J (1969) 1.42
Novel THAP1 sequence variants in primary dystonia. Neurology (2010) 1.42
Lower cardiac mortality in smokers following thrombolysis for acute myocardial infarction may be related to more effective fibrinolysis. QJM (1999) 1.41
Essential tremor: predictors of disease progression in a clinical cohort. J Neurol Neurosurg Psychiatry (2006) 1.41
Inequalities and health. Lancet (1994) 1.40
Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain (2009) 1.40
[The first report of the rickettsial infections of spotted fever group in Japan: three clinical cases]. Kansenshogaku Zasshi (1985) 1.39
Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology (2008) 1.39
Hereditary form of parkinsonism--dementia. Ann Neurol (1998) 1.39
Parkinson disease: handedness predicts asymmetry. Neurology (2005) 1.37